Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemarituzumab + S-1 + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Bemarituzumab is a first-in-class humanized IgG1 monoclonal antibody that selectively targets the fibroblast growth factor receptor 2b (FGFR2b), a protein overexpressed in approximately 30% of non-HER2-positive gastric and gastroesophageal junction (GEJ) cancers. Developed by Amgen following its acquisition of Five Prime Therapeutics, bemarituzumab is being evaluated in the FORTITUDE-103 trial in combination with the SOX chemotherapy regimen, which consists of the oral fluoropyrimidine S-1 (a combination of tegafur, gimeracil, and oteracil) and the platinum-based agent oxaliplatin. Bemarituzumab works by blocking the binding of FGF ligands to FGFR2b, thereby inhibiting downstream signaling pathways that drive tumor cell proliferation and survival, and it may also induce antibody-dependent cellular cytotoxicity (ADCC). The SOX regimen provides complementary cytotoxic activity through DNA cross-linking and inhibition of thymidylate synthase.
- Other names
- bemarituzumab + SOXbemarituzumab + S-1 + oxaliplatin
02
Targets
DNAFGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FGFR2 (Keratinocyte growth factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on bemarituzumab + S-1 + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemarituzumab + S-1 + oxaliplatin.